Knight Therapeutics (GUD) Stock Forecast & Price Target

Knight Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 3 Analyst Ratings

Sell
0

Hold
0

Buy
3

Consensus Price Target

C$7.08
N/A

Get the Latest News and Ratings for GUD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Knight Therapeutics and its competitors.

GUD Analyst Ratings Over Time

Type	Current Forecast 12/5/23 to 12/4/24	1 Month Ago 11/5/23 to 11/4/24	3 Months Ago 9/6/23 to 9/5/24	1 Year Ago 12/5/22 to 12/5/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	1 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	C$7.08	C$7.08	C$7.08	C$5.92
Forecasted Upside	N/A	25.37% Upside	26.04% Upside	15.33% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

Elon Musk’s chilling warning for humanity (Ad)

The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.

Go here to see why.

GUD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GUD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Knight Therapeutics Stock vs. The Competition

Type	Knight Therapeutics	Medical Companies
Consensus Rating Score	3.33	2.81
Consensus Rating	Buy	Moderate Buy
News Sentiment Rating	Neutral News See Recent GUD News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/15/2024	Raymond James 4 of 5 stars	M. Freeman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
8/13/2024	Stifel Nicolaus 4 of 5 stars		Upgrade	Hold ➝ Buy	C$5.75 ➝ C$6.75	+17.19%
8/12/2024	Stifel Canada 5 of 5 stars	J. Keywood Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
3/22/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	C$6.50 ➝ C$7.00	+32.58%
3/24/2023	National Bank Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Leno Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform Market Weight ➝ Sector Perform Market Weight
3/24/2023	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Sector Perform	C$7.75 ➝ C$6.00	+32.45%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:59 AM ET.

GUD Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Knight Therapeutics is C$7.08, with a high forecast of C$7.50 and a low forecast of C$6.75.
: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GUD shares.
: According to analysts, Knight Therapeutics's stock has a predicted upside of ∞ based on their 12-month stock forecasts.
: Over the previous 90 days, Knight Therapeutics's stock had 1 upgrade by analysts.
: Knight Therapeutics has been rated by research analysts at Raymond James in the past 90 days.
: Analysts like Knight Therapeutics more than other "medical" companies. The consensus rating for Knight Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GUD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

This page (TSE:GUD) was last updated on 12/4/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Knight Therapeutics (GUD) Stock Forecast & Price Target